Cerus Competitors

Cerus (NASDAQ:CERS) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

82.1% of Cerus shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 6.5% of Cerus shares are held by insiders. Comparatively, 1.2% of Align Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cerus and Align Technology, as provided by MarketBeat.

Cerus presently has a consensus target price of $7.8333, suggesting a potential upside of 27.79%. Align Technology has a consensus target price of $501.3333, suggesting a potential downside of 15.40%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts clearly believe Cerus is more favorable than Align Technology.

Risk & Volatility

Cerus has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Profitability

This table compares Cerus and Align Technology's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Cerus and Align Technology's revenue, earnings per share (EPS) and valuation.

Align Technology has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Align Technology beats Cerus on 11 of the 14 factors compared between the two stocks.

Cerus (NASDAQ:CERS) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

82.1% of Cerus shares are held by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are held by institutional investors. 6.5% of Cerus shares are held by insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cerus and West Pharmaceutical Services, as provided by MarketBeat.

Cerus presently has a consensus target price of $7.8333, suggesting a potential upside of 27.79%. West Pharmaceutical Services has a consensus target price of $310.00, suggesting a potential upside of 4.55%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts clearly believe Cerus is more favorable than West Pharmaceutical Services.

Risk & Volatility

Cerus has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.

Profitability

This table compares Cerus and West Pharmaceutical Services' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Cerus and West Pharmaceutical Services' revenue, earnings per share (EPS) and valuation.

West Pharmaceutical Services has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Summary

West Pharmaceutical Services beats Cerus on 8 of the 14 factors compared between the two stocks.

Cerus (NASDAQ:CERS) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Cerus and The Cooper Companies' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Cerus and The Cooper Companies' revenue, earnings per share (EPS) and valuation.

The Cooper Companies has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cerus has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Institutional & Insider Ownership

82.1% of Cerus shares are held by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are held by institutional investors. 6.5% of Cerus shares are held by insiders. Comparatively, 1.4% of The Cooper Companies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cerus and The Cooper Companies, as provided by MarketBeat.

Cerus presently has a consensus target price of $7.8333, suggesting a potential upside of 27.79%. The Cooper Companies has a consensus target price of $384.25, suggesting a potential downside of 0.47%. Given Cerus' stronger consensus rating and higher possible upside, equities analysts clearly believe Cerus is more favorable than The Cooper Companies.

Summary

The Cooper Companies beats Cerus on 9 of the 14 factors compared between the two stocks.

Cerus (NASDAQ:CERS) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cerus and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Cerus and DENTSPLY SIRONA's revenue, earnings per share (EPS) and valuation.

DENTSPLY SIRONA has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cerus has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Institutional and Insider Ownership

82.1% of Cerus shares are owned by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are owned by institutional investors. 6.5% of Cerus shares are owned by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cerus and DENTSPLY SIRONA, as provided by MarketBeat.com.

Cerus presently has a consensus price target of $7.8333, suggesting a potential upside of 27.79%. DENTSPLY SIRONA has a consensus price target of $55.3333, suggesting a potential downside of 13.81%. Given Cerus' stronger consensus rating and higher possible upside, research analysts plainly believe Cerus is more favorable than DENTSPLY SIRONA.

Summary

DENTSPLY SIRONA beats Cerus on 8 of the 14 factors compared between the two stocks.

Cerus (NASDAQ:CERS) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cerus and Haemonetics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Cerus and Haemonetics' revenue, earnings per share (EPS) and valuation.

Haemonetics has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cerus has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.

Institutional and Insider Ownership

82.1% of Cerus shares are owned by institutional investors. Comparatively, 96.2% of Haemonetics shares are owned by institutional investors. 6.5% of Cerus shares are owned by insiders. Comparatively, 1.6% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cerus and Haemonetics, as provided by MarketBeat.com.

Cerus presently has a consensus price target of $7.8333, suggesting a potential upside of 27.79%. Haemonetics has a consensus price target of $144.80, suggesting a potential upside of 23.70%. Given Cerus' higher possible upside, research analysts plainly believe Cerus is more favorable than Haemonetics.

Summary

Haemonetics beats Cerus on 9 of the 13 factors compared between the two stocks.

Cerus (NASDAQ:CERS) and STAAR Surgical (NASDAQ:STAA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cerus and STAAR Surgical's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Cerus and STAAR Surgical's revenue, earnings per share (EPS) and valuation.

STAAR Surgical has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cerus has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

Institutional and Insider Ownership

82.1% of Cerus shares are owned by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are owned by institutional investors. 6.5% of Cerus shares are owned by insiders. Comparatively, 3.9% of STAAR Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Cerus and STAAR Surgical, as provided by MarketBeat.com.

Cerus presently has a consensus price target of $7.8333, suggesting a potential upside of 27.79%. STAAR Surgical has a consensus price target of $68.50, suggesting a potential downside of 40.92%. Given Cerus' stronger consensus rating and higher possible upside, research analysts plainly believe Cerus is more favorable than STAAR Surgical.

Summary

STAAR Surgical beats Cerus on 9 of the 13 factors compared between the two stocks.